Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 3-9

  Makhija, S ^a   Sit, A ^b   Edwards, R ^b   Aufman, K ^b   Weiss, H ^c   Kanbour Shakir, A ^b   Gooding, W ^d   D'Angelo, G ^d   Ferrell, R ^e   Raja, S ^d   Godfrey, T E ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer; Chemoresistance; Chromosome 6; Ovary; Quantitative microsatellite analysis

Indexed keywords

CISPLATIN; MICROSATELLITE DNA; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIZATION; FEMALE; FISHER EXACT TEST; GENE PROBE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ADENOCARCINOMA; DRUG RESISTANCE; GENETICS; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OVARY TUMOR; PATHOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; NUCLEIC ACID HYBRIDIZATION; OVARIAN NEOPLASMS;

EID: 0038500746     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00177-X     Document Type: Article

References (30)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin. 51:2001;15-37.
2. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or stage IV ovarian cancer a Gynecologic Oncology Group study . J Clin Oncol. 18:2000;106-115.
3. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
4. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol. 124:1998;326-328.
5. Coukos G., Rubin S. Chemotherapy resistance in ovarian cancer new molecular perspectives . Obstet Gynecol. 91:1998;783-792.
6. Kudoh K., Takano M., Koshikawa T., et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res. 5:1999;2526-2531.
7. Kallioniemi A., Kallioniemi O.P., Sudar D., Rutovitz D., Gray J.W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 258:1992;818-821.
8. Sakamoto M., Umayahara K., Sakamoto H., Kawasaki K., Suehiro Y., Kunugi T., et al. Cancer-associated gene abnormalities and chemosensitivity. Gan To Kagaku Ryoho. 25:1998;1819-1831.
9. Wasenius V.M., Jekunen A., Monni O., Joensuu H., Aebi S., Howell S.B., Knuutila S. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer. 18:1997;286-291.
10. DeRisi J., Penland L., Brown P.O., Bittner M.L., Meltzer P.S., Ray M., et al. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet. 14:1996;457-460.
11. Holland P.M., Abramson R.D., Watson R., Gelfan D.H. Detection of specific polymerase chain reaction product by utilizing the 5′ - 3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA. 88:1991;276-280.
12. Gibson U.E., Heid C.A., William P.M. A novel method for real time quantitative RT-PCR. Genome Res. 6:1996;995-1001.
13. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 6:1996;986-994.
14. Bieche I., Olivi M., Champeme M.H., Vidaud D., Lidereau R., Vidaud M. Novel approach to quantitative polymerase chain reaction using realtime detection application to the detection of gene amplification in breast cancer . Int J Cancer. 78:1998;661-666.
15. Bieche I., Laurendeau I., Tozlu S., Olivi M., Vidaud D., Lidereau R., Vidaud M. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 59:1999;2759-2765.
16. Chiang P.W., Beer D.G., Wei W.L., Orringer M.B., Kurnit D.M. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res. 5:1999;1381-1386.
17. Ginzinger D.G., Godfrey T.E., Nigro -J., Moore D., Suzuki S., Pallavicini M.G., et al. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res. 60:2000;5405-5409.
18. Suzuki S., Moore D., Ginzinger D.G., Godfrey T.E., Barclay J., Powell B., et al. An approach to large-scale correlations between genome changes and clinical endpoints. Cancer Res. 60:2000;5382-5385.
19. PE Applied Biosystems User Bulletin #2. Relative quantitation of gene expression [pamphlet]. 1997.
20. Collins C., Rommens J.M., Kowbel D., Godfrey T., Tanner M., Hwang S.I., et al. Positional cloning of ZNF217 and NABC1 genes amplified at 20q13.2 and overexpressed in breast carcinoma . Proc Natl Acad Sci USA. 95:1998;8703-8708.
21. Hahn G., Meeker W. Statistical intervals a guide for practitioners . 1991;Wiley, New York.
22. Kim J., Skates S.J., Uede T., Wong K., Schorge J., Feltmate C., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 287:2002;1671-1679.
23. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
24. Jones M.B., Krutzsch H., Shu H., Zhao Y., Liotta L.A., Kohn E.C., Petricoin E.F. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics. 2:2002;76-84.
25. Mills G.F., Bast R.C., Srivastava S. Future for ovarian cancer screening novel markers from emerging technologies of transcriptional profiling and proteomics . J Natl Cancer Inst. 93:2001;1437-1439.
26. Colitti C., Rodabaugh K., Welch W., Berkowitz R., Mok S. A novel 4 cM minimal deletion unit on chromosome 6q25.10q25.2 associated with high grade invasive epithelial ovarian carcinomas. Oncogene. 16:1998;555-559.
27. Oates A., Schumaker L., Jenkins S., et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat. 47:1998;269-281.
28. Lee A., Hilsenbeck S., Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat. 47:1998;295-302.
29. Wood T., Richert M., Stull M., Allar M. The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mamm Gland Biol Neoplasia. 5:2000;31-42.
30. Yee D., Lee A. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mamm Gland Biol Neoplasia. 5:2000;107-115.